RxDoctor Payments Data

Alejandra Rodriguez-Paez, MD

Rheumatology · Morton Grove, ILNPI 1356556013

Payments from drug & device makers

$12,873in general payments, 2019–2025

Across 37 payments — averaging $347.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$5K
  • AbbVie$3K
  • Aurinia Pharma U.S., Inc.$3K
  • Fresenius Kabi USA, LLC$1K
  • UCB, Inc.$373
  • PBG Puerto Rico LLC$92
  • plus $243 from 3 others

What the payments were for

  • Consulting fees$4,90038%
  • Speaking & faculty fees$4,64036%
  • Travel & lodging$4273%
  • Food & beverage$2,90623%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen(2 entities)15$5,183
AbbVie10$2,877
Aurinia Pharma U.S., Inc.2$2,804
Fresenius Kabi USA, LLC1$1,300
UCB, Inc.3$373
PBG Puerto Rico LLC1$92
Medtronic1$89
Novartis1$87
Johnson & Johnson3$67

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,873 in reported general payments places this provider in the 75th percentile of 287 rheumatology providers in Illinois.

See all rheumatology providers in Illinois

Medicare billing

Part B allowed, 2024
$3,887,046
Medicare patients
871
Services billed
272,404

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab35$347,284
RinvoqUpadacitinib32$240,313
Humira(Cf)Adalimumab22$151,681
XeljanzTofacitinib Citrate19$120,293
Enbrel SureclickEtanercept12$111,745
EnbrelEtanercept13$100,591
HumiraAdalimumab15$99,350
Xeljanz XrTofacitinib Citrate11$74,532
Cimzia (2 Pack)Certolizumab Pegol11$58,741
Celecoxib299$15,663
MethotrexateMethotrexate Sodium332$13,704
Hydroxychloroquine Sulfate237$10,193
Leflunomide110$8,812
Gabapentin530$7,866
Duloxetine Hcl291$6,918

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Humira(Cf), Humira$2,877$491,34469 claims
AmgenEnbrel$5,183$100,59113 claims
UCB, Inc.Cimzia (2 Pack)$373$58,74111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 287 rheumatology providers in Illinois.

Other rheumatology in Morton Grove

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →